# Context Therapeutics Context Therapeutics is an Asset Manager based in Philadelphia, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Philadelphia, United States - **Region:** North America - **Address:** Philadelphia, PA, United States - **Founded:** 2015 - **Assets under management:** Undisclosed - **Website:** contexttherapeutics.com ## Regulatory record - **Reports private funds:** No ## About Lehr established Context Therapeutics in 2015, headquartered in Philadelphia, to address a specific gap in oncology drug development: hormone-responsive cancers that become refractory to first-line treatments. The company is not a diversified manager but a clinical-stage biopharmaceutical firm with a concentrated pipeline centered on onapristone extended release (ONA-XR), a progesterone receptor antagonist licensed from Arno Therapeutics. The asset targets progesterone receptor-positive cancers, an under-exploited mechanism in solid tumors, positioning Context to build a franchise around a single, biologically plausible axis. Context maps its capital almost entirely into clinical advancement of internal assets. The lead program targets granulosa cell tumors of the ovary and recurrent endometrial cancer, two indications with limited approved therapies. A Phase 2 trial (ONWARD 220) for ovarian cancer began enrollment in 2022, evaluating ONA-XR in combination with an aromatase inhibitor. The therapeutic footprint extends into breast cancer and other progesterone-driven malignancies through investigator-sponsored trials, keeping the company's own capital deployment concentrated on the registration-enabling studies it fully controls. The geographic focus is the United States for clinical trial execution, with global licensing optionality retained. The firm operates with a lean public-company structure, filing with the SEC as a smaller reporting company. As of early 2024, Context held a cash position of approximately $11 million, with periodic raises through registered direct offerings and a 2023 private placement. The company's Nasdaq listing (ticker: CNTX) and periodic retail-oriented financing rounds reflect a biotech that funds incrementally — a posture distinct from institutionally-backed peers. There are no disclosed adjacent vehicles, real-asset arms, or philanthropic structures. Context's structural differentiator lies in its single-asset architecture. The company's entire valuation rests on the clinical trajectory of ONA-XR. This concentration removes the diversification safety net but creates sharp alignment between management's development decisions and shareholder outcomes. The exclusive license from Arno Therapeutics, combined with a trial design that uses a companion diagnostic to screen for progesterone receptor-positivity, builds a narrow but defensible precision-oncology moat that a larger, multi-asset firm would be unlikely to allocate equivalent focus toward. ## Sectors - Oncology - Biotechnology ## People - Martin Lehr — Chief Executive Officer - Jennifer Minai-Azary — Chief Financial Officer ## Questions ### What is the core scientific mechanism behind Context Therapeutics' lead asset? The lead asset, onapristone extended release (ONA-XR), is a progesterone receptor antagonist. It works by blocking progesterone receptor signaling, which certain cancers hijack to drive growth even after estrogen receptor pathways are suppressed. This mechanism is particularly relevant in progesterone receptor-positive ovarian granulosa cell tumors and recurrent endometrial cancer, where hormonal escape is a resistance pathway not addressed by standard aromatase inhibitors alone. ### How does Context Therapeutics fund its clinical development without a recurring revenue stream? Context funds operations primarily through periodic equity raises as a publicly listed company. The firm has used registered direct offerings, private placements, and at-the-market (ATM) facilities to extend its cash runway. Because the organization is lean and the pipeline is concentrated on a single Phase 2-stage asset, capital requirements are lower than for a multi-program biotech, but the company remains dependent on investor appetite for its specific oncology thesis. ### Is Context Therapeutics involved in drug discovery, or is it purely a clinical development company? Context is structured as a clinical development and licensing company, not a discovery platform. Its lead asset, ONA-XR, was in-licensed from Arno Therapeutics. The firm focuses on clinical trial execution, regulatory strategy, and building intellectual property around specific therapeutic indications for that molecule, including combination regimens and patient-selection methods using a companion diagnostic. ### Does Context Therapeutics have any partnership arrangements with larger pharmaceutical companies? As of the latest public disclosures, Context has not announced any co-development or commercialization partnership with a large pharmaceutical company. The firm retains full rights to ONA-XR under its license from Arno, managing the clinical program independently. Investigator-sponsored trials at academic centers supplement the company-sponsored work but represent research collaborations rather than commercial partnerships. ## Related profiles - [Gold Resource Corp](https://altss.com/profile/gold-resource-corp) - [Tiziana Life Sciences](https://altss.com/profile/tiziana-life-sciences-ltd) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/context-therapeutics-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology